Xeris Biopharma Holdings, Inc. XERS Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s investing cash flow?
- Xeris Biopharma Holdings, Inc. (XERS) reported investing cash flow of -$325K in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s investing cash flow changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s investing cash flow decreased by 2400.0% year-over-year, from -$13K to -$325K.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s investing cash flow?
- Over 2 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s investing cash flow has grown at a -91.6% compound annual growth rate (CAGR), from $97.96M to -$696K.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.